US-based drug firm Mylan today said its Indian arm has received a nod from the country’s drug regulator DCGI to market its antiretroviral drug Avonza.

Mylan Pharmaceuticals Private Ltd, a subsidiary of Mylan N V, has received marketing authorisation from the Drug Controller General of India (DCGI) for its antiretroviral drug Avonza, the company said in a statement.

The product is recommended by the World Health Organisation (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS, it added.

“Developing Avonza and bringing it to patients with HIV in India is a continuation of our strong and sustained commitment to expanding access to affordable, high quality ARVs,” Mylan President Rajiv Malik said.

Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs, he added.

The company’s comprehensive ARV portfolio includes 14 active pharmaceutical ingredients and 50 finished dosage forms in first-line, second-line and paediatric formulations, Mylan said.